Therefore, it may be suggested that the benefit of anti-VEGF therapy could also originate from RPE recovery in cases where RPE migration or proliferation is observable in polarization-sensitive OCT, and not solely from resolution of retinal edema. The gene discussed is VEGFA; the disease is retinal edema.